Bupropion for the Treatment of Methamphetamine Dependence - 1

January 11, 2017 updated by: National Institute on Drug Abuse (NIDA)

Bupropion for the Treatment of Methamphetamine Dependence

The purpose of this study is to assess the efficacy and safety of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

A double-blind, placebo-controlled, parallel-group design study in which 100 subjects will be randomly assigned to placebo or bupropion for 12 weeks with follow-up assessments 4 weeks following treatment. Adaptive randomization will be used to balance treatment groups based on gender.

Study Type

Interventional

Enrollment

150

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • California
      • Costa Mesa, California, United States, 92627
        • Matrix Institute on Addictions
      • San Diego, California, United States, 92105
        • South Bay Treatment Center
    • Hawaii
      • Honolulu, Hawaii, United States, 96813
        • Pacific Addiction Research Center
    • Iowa
      • Des Moines, Iowa, United States, 50316
        • Powell Chemical Dependency Center
    • Missouri
      • Kansas City, Missouri, United States, 64108
        • University of Missouri - Kansas City

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Subject must have methamphetamine dependence as determined by the DSM-IV diagnosis
  • Subject must be willing to comply with study procedures.
  • Ability to verbalize understanding of consent form, provide written consent, and verbalize willingness to complete study procedures
  • Be able to comply with protocol requirements

Exclusion Criteria:

  • Please contact site for more information.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: DOUBLE

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Severity addiction
Methamphetamine use

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

National Institute on Drug Abuse (NIDA)

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2003

Study Completion

June 1, 2005

Study Registration Dates

First Submitted

September 18, 2003

First Submitted That Met QC Criteria

September 23, 2003

First Posted (ESTIMATE)

September 24, 2003

Study Record Updates

Last Update Posted (ESTIMATE)

January 12, 2017

Last Update Submitted That Met QC Criteria

January 11, 2017

Last Verified

July 1, 2008

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NIDA-CTO-0008-1

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Amphetamine-Related Disorders

Clinical Trials on Bupropion

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe